Hexaxim vaccine safety confirmed in 713 korean infants
NCT ID NCT06793826
First seen Feb 24, 2026 · Last updated May 22, 2026 · Updated 19 times
Summary
This study looked at the safety of the Hexaxim vaccine, which protects against diseases like hepatitis B and Haemophilus influenzae type b, in infants starting at 2 months old in South Korea. Researchers tracked side effects like pain, swelling, fever, and crying in 713 babies who received the vaccine as part of routine care. The goal was to make sure the vaccine is safe for everyday use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number : 001
Seoul, South Korea
-
Investigational Site Number : 002
Cheonan, South Korea
Conditions
Explore the condition pages connected to this study.